Luxa’s Expanded Access Policy

“Expanded Access” refers to the use of an investigational product outside of a clinical trial for potential treatment of a serious or life-threatening condition. Luxa Biotechnology is developing allogeneic Retinal Pigment Epithelium Stem Cells (RPESC-RPE-4W) for patients with failing vision due to Dry Age Related Macular Degeneration (Dry AMD). Luxa is committed to bringing an innovative, safe, and effective product to patients suffering from vision loss due to Dry AMD.  As a result, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approval to make our RPESC-RPE-4W product broadly available as quickly and safely as possible.  Participation in our clinical trial at one of our clinical trial sites is the best and preferred route to access this investigational product. Luxa does not currently have any active Expanded Access protocols nor do we currently provide access to our investigational products on an Expanded Access basis. We encourage patients interested in our investigational RPESC-RPE-4W product to learn more about our ongoing studies or to see if they are eligible for inclusion in an ongoing clinical trial by visiting clinicaltrials.gov or by contacting us via email at: mailto:info@Luxabiotech.com

Luxa will respond to inquiries within 5 business days from receipt.